# Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

Study · id `cardio:ct-nct06779630` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06779630](<https://clinicaltrials.gov/study/NCT06779630>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06779630

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 150 participants.

## Technical summary

Registry record NCT06779630. Allocation not applicable; no masking; primary purpose treatment. Start 2025-07-18 (actual); primary completion 2027-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT06779630, source copy `cardio:ctgov-nct06779630-2026-11-05`, retrieved 2026-11-18)
- Started: 2025-07-18 (actual) (ClinicalTrials.gov record NCT06779630, source copy `cardio:ctgov-nct06779630-2026-11-05`, retrieved 2026-11-18)
- Primary completion: 2027-09 (anticipated) (ClinicalTrials.gov record NCT06779630, source copy `cardio:ctgov-nct06779630-2026-11-05`, retrieved 2026-11-18)
- Completion: 2031-09 (anticipated) (ClinicalTrials.gov record NCT06779630, source copy `cardio:ctgov-nct06779630-2026-11-05`, retrieved 2026-11-18)
- Countries: United States; Austria; France; Germany; Poland; Switzerland (ClinicalTrials.gov record NCT06779630, source copy `cardio:ctgov-nct06779630-2026-11-05`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06779630-2026-11-05`, retrieved 2026-11-18)

## The registry's words

- Brief title: Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
- Acronym: BIOFLOW-48
- Condition: Coronary Artery Disease
- Intervention (Device): Orsiro Mission 48-mm Sirolimus-Eluting Coronary Stent System
- Lead sponsor: Teleflex
- Lead sponsor class: INDUSTRY
- Collaborator: BIOTRONIK AG (A Teleflex Company)
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Teleflex (`cardio:org-teleflex`)

## Provenance

Content hash: 733b44fc7ca416cf3c9c48269b09c9ad6efb7b133909a8a75f97b6b2244ba66f
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
